HDG, Re: your Possibility, I can forsee a day when the scripts for the Marine indication are far less than 1% of the Vascepa Market. "Skinny Market" will be pushing the limits of non-microscopic visibilty. For the sake of discussion, I assume that I can prove how skinny it is. Now let's assume that Hikma dumps on the market 50% of the units needed to supply the Vascepa demand and it gets gobbled up for the Reduce-it indication. Add to that the fact that Hikma gave financial projections to the World for a generic market stratospherically greater than the Marine label. It seems clear that they are knowingly trying to induce someone to do something to start an avalanche of demand for Non-Marine label Vascepa. Now give me a Jury trial in a friendly jurisdiction where regular folks can see what federal judges may chose to overlook. I would think/hope that a skinny label can become so small, that it no longer legally exists. I must assume that Hikma and Singer have already figured this out. Amarin still has another life.
News 
Market Data 
Discover 
AI
